• Success Rate on the Investigator's Global Assessment [ Time Frame: at week 12 ] [ Designated as safety issue: No ]
• Changes in Inflammatory Lesion Counts [ Time Frame: from Baseline to week 12 ] [ Designated as safety issue: No ]
• Changes in Noninflammatory Lesion Counts [ Time Frame: from Baseline to week 12 ] [ Designated as safety issue: No ]

• Success Rate on the Investigator’s Global Assessment
• Change in Inflammatory Lesion Counts
• Change in Noninflammatory Lesion Counts

• Percent Change in Inflammatory Lesion Counts [ Time Frame: at week 12 ] [ Designated as safety issue: No ]
• Percent Change in Noniflammatory Lesion Counts [ Time Frame: at week 12 ] [ Designated as safety issue: No ]
• Percent Change in Total Lesion Counts [ Time Frame: at week 12 ] [ Designated as safety issue: No ]

• Percent Change in Lesion Counts (Inflammatory,Noninflammatory, Total)
• Change in Investigator’s Global Assessment (IGA)
• Subject’s Assessment of Acne

This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris. Efficacy and safety evaluations will be performed at Screening (safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a subject should remain the same during the study.

The primary objective is to demonstrate the superiority in efficacy and assess safety of Adapalene/Benzoyl Peroxide Topical Gel (Adapalene/Benzoyl Peroxide Gel) versus Adapalene Topical Gel, 0.1% (Adapalene Monad); Benzoyl Peroxide Topical Gel, 2.5% (Benzoyl Peroxide Monad) and Topical Gel Vehicle (Gel Vehicle) in the treatment of acne vulgaris for up to 12 weeks.

• Drug: Adapalene/Benzoyl Peroxide
• Drug: Adapalene
• Drug: Benzoyl Peroxide
• Drug: Topical Gel Vehicle

• Experimental: Adapalene/Benzoyl Peroxide Topical Gel
• Active Comparator: Adapalene Topical Gel
• Active Comparator: Benzoyl Peroxide Topical Gel
• Placebo Comparator: Topical Gel Vehicle

Inclusion Criteria:

• A clinical diagnosis of acne vulgaris with facial involvement.
• A minimum of 20 but not more than 50 Inflammatory lesions
• A minimum of 30 but not more than 100 Noninflammatory lesions
• A score of 3 (Moderate) on the Investigator's Global Assessment Scale.

Exclusion Criteria:

• More than one acne nodule or any acne cyst.
• Acne conglobata, acne fulminans, secondary acne, or severe acne.
• Known previous participation in an Adapalene/Benzoyl Peroxide Topical Gel Trial.
• Underlying diseases that require the use of interfering topical or systemic therapy.
• Use of prohibited medications prior to the study unless appropriate washout period is documented
• Use of hormonal contraceptives solely for control of acne